- Previous Close
0.0000 - Open
0.3802 - Bid 0.2200 x --
- Ask 0.2580 x 317700
- Day's Range
0.1500 - 0.3802 - 52 Week Range
0.1500 - 7.9000 - Volume
169,446 - Avg. Volume
0 - Market Cap (intraday)
994,994 - Beta (5Y Monthly) --
- PE Ratio (TTM)
0.61 - EPS (TTM)
0.3600 - Earnings Date Apr 7, 2025 - Apr 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
34.00
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California. On December 27, 2024, Biora Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
www.bioratherapeutics.comRecent News: BIOR
View MorePerformance Overview: BIOR
Trailing total returns as of 4/7/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BIOR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BIOR
View MoreValuation Measures
Market Cap
994.99k
Enterprise Value
37.44M
Trailing P/E
0.61
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.74
Price/Book (mrq)
--
Enterprise Value/Revenue
41.98
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
--
Diluted EPS (ttm)
0.3600
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--